Full Press Release Details
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies.
ZLAB
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Key Takeaway: argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Price reaction · baseline $26.15 (2024-11-19 close) · hit after-hours · 1 other ZLAB headline(s) in the window, move may be shared
day 0 close
+0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer